* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download document
Survey
Document related concepts
Immunocontraception wikipedia , lookup
Hygiene hypothesis wikipedia , lookup
DNA vaccination wikipedia , lookup
Molecular mimicry wikipedia , lookup
Sjögren syndrome wikipedia , lookup
Immune system wikipedia , lookup
Multiple sclerosis research wikipedia , lookup
Adaptive immune system wikipedia , lookup
Adoptive cell transfer wikipedia , lookup
Monoclonal antibody wikipedia , lookup
Innate immune system wikipedia , lookup
Polyclonal B cell response wikipedia , lookup
Cancer immunotherapy wikipedia , lookup
Transcript
Basic Immunology 101 Amy Sharma Ph.D. Candidate Uetrecht Laboratory Leslie Dan Faculty of Pharmacy, University of Toronto Q. Why does your immune system exist? Immunology Overview Immune system is like a double edged sword Key players of the immune system Humoral versus Cellular Immunity I. Cells of the immune system T-lymphocytes (Thymus derived ‘T’ cells) Key role in cell-mediated immunity • co-ordinate and regulate immune responses through cytokine activation, antibody stimulation, etc Constitute ~60-70% of lymphocytes in circulating blood Many different sub-types Identified by T-cell receptor I. Cells of the immune system B-lymphocytes (Bone marrow derived ‘B’ cells) Key role in humoral immunity: • produce antibodies against antigens • act as antigen-presenting cells (APCs) • develop into memory B cells after activation by antigen interaction Constitute ~10-20% of lymphocytes in circulating blood I. Cells of the immune system Macrophages (“Big-eaters”) Key role in immunity in general: • main type of APC (process and present antigen to CD4+ Th-cells) • phagocytose and kill microbes coated by antibody and/or complement • produce cytokines, regulating T and B cell function I. Cells of the immune system Dendritic cells (“Potent” APC) Key role: link between adaptive and cell mediated immunity • process antigen and present peptide fragments to other cells of the immune system goes on to regulate T and B cell responses I. Cells of the immune system Natural Killer ‘NK’ cells (“LGL’s”) Key role in cell-mediated immunity • contain azurophilic granules thus capable of lysing tumor cells, virus infected cells, etc, without previous sensitization Constitute ~10-15% of lymphocytes in circulating blood Innate Immunity (cellular immunity) Mediated by lymphocytes Does not involve antibodies (antigen nonspecific) Cellular immunity protects the body by: • activating macrophages, NK cells, and cytotoxic T-cells • stimulating cytokine secretion, influencing the function of other immune cells Humoral Immunity Mediated by soluble antibody proteins (antigen specific) Humoral immunity protects the body by: • antigen presentation, discriminating recognition of “non-self” versus “self” • the generation of antibody responses • the development of immune memory Idiosyncratic Drug Reactions What are They, Why & How Do We Study Them? Amy Sharma Ph.D. Candidate Uetrecht Laboratory Leslie Dan Faculty of Pharmacy, University of Toronto Overview I. II. III. IV. V. VI. VII. Adverse Drug Reactions (ADRs) Idiosyncratic Drug Reactions (IDRs) Characteristics of IDRs Proposed Mechanism of IDRs Drugs Known to Induce IDRs Studying IDRs Future Directions I. Adverse Drug Reactions I. Adverse Drug Reactions The World Health Organization definition: “any noxious, unintended, and undesired effect of a drug, which occurs at doses used in humans for prophylaxis, diagnosis, or therapy” ADRs are common • • 2,216,000 hospitalized patients/year experienced a serious ADR and 106,000/year died from an ADR Fatal ADRs rank 4th to 6th in leading causes of death in US (Bond CA et al. Pharmacotherapy 2006) I. Adverse Drug Reactions I. Adverse Drug Reactions Adverse drug reactions can be divided into five basic types: Type A (augmented): • Can be predicted from the pharmacology of the drug • Are typically dose-dependent Type C (chemical), D (delayed) and E (end of treatment) Type B: • Cannot be predicted on the basis of the known pharmacology of the drug • Also known as idiosyncratic adverse reactions • Can affect almost any organ system II. Idiosyncratic Drug Reactions Rare & unpredictable reactions • • • Do not occur in most patients at any dose • Incidence: 1/103 - 1/106 patients 25% of all ADRs Still very prevalent because of the number of drugs involved and the number of people taking these drugs No simple dose-response relationship Effects not related to pharmacological properties of the drug Can be very severe • most serious ADRs in drug therapy III. Characteristics of IDRs Organs affected: Liver Skin (cholestatic liver) (mild-severe rash) Bone marrow / Blood cells (aplastic anemia; agranulocytosis) Most thought to be immune-mediated Detected during the late stage of development or when drug is released on to market May lead to withdrawal Significant financial burden III. Risk Factors for IDRs: Don’t have a good understanding of who will develop IDRs. Age - Incidence increases with age Concomitant challenge – increase risk for HIV patients Ethnic background – Incidence of clozapineinduced agranulocytos is 20% in a Jewish hospital vs. <1% elsewhere Gender - female >> male IV. Mechanisms of IDRs If we can understand how drugs induce IDRs we can: Scan for drugs that have high risk of causing IDRs early in the drug development process, and avoid later losses to both patients and manufacturers Devise therapy that prevents IDRs in patients (administer concomitant therapy) There is circumstantial evidence that indicates a potential role of reactive metabolites (RMs) in development of IDRs IV. Step 1: Reactive Metabolite Formation Drug Metabolism: • Process whereby therapeutically active drugs are converted to a more soluble form (metabolites) and are cleared by renal or biliary excretion Reactive Metabolites (RMs) and Covalent Binding • During metabolism, usually through P450 oxidation, drugs can form RMs (chemically reactive species) that can covalently bind to endogenous proteins or other macromolecules Reactive Metabolites Reactive metabolites are electrophiles or free radicals • • • • Sulfates/sulfonates Epoxides/arene oxides Michael Acceptors Nitroso amines IV. Where Does Metabolism Occur? Metabolizing enzymes are present in the following organs: Cytochrome P450, Sulphotransferases, Peroxidases White blood cells (macrophages and neutrophils) that become activated to kill bacteria, and do so by releasing oxidants such as H2O2 and HOCl. IV. Where Does Metabolism Occur? Once formed, reactive metabolites tend to bind to nucleophilic groups on proteins or macromolecules near the site of their formation. Thus, toxicity most often occurs at sites of RM formation, especially if RM is highly reactive! Example – Clozapine: Clozapine is oxidized to a RM in both the liver and neutrophils. The main toxic effects of clozapine are liver and neutrophil toxicity (hepatotoxicity and agranulocytosis). IV. Step 2: Immune Response Basic paradigm in Immunology • To discriminate against pathogens, the immune system learns to recognize self from non-self. In this way, autoimmunity is avoided and immune responses are mounted against foreign invaders. Hapten Hypothesis • Once drug is covalently bound to a host protein it forms a novel antigen known as the hapten-carrier complex. Host immune system then perceives the modified endogenous protein as foreign, and mounts an immune response against it. IV. Hapten Hypothesis Detailed Step 1 – Reactive Metabolite Formation Step 2 – T-cell activation and Initiation of an Immune Response IDR IV. T-cell Activation IV. IDR Characteristics that Indicate Immune Involvement 1. Reaction takes several weeks to develop 2. Once the drug is removed, reaction clears quickly 3. On re-exposure the time to onset is shorter than on first exposure 4. In some reactions anti-hapten antibodies or antibodies against self-tissues are found (e.g., in patients with halothane-induced hepatitis anti-hapten antibodies have been found) Not all IDRs have these characteristics V. Clinical Evidence in Support of Hapten Hypothesis Penicillin-induced anaphylaxis Aminopyrine-induced agranulocytosis Halothane-induced hepatitis V. Penicillin-Induced Anaphylaxis -lactam ring O C C H2 S NH N O Benzylpenicillin CH3 CH3 COOH O C C H2 S CH NH 3 O C HN CH3 NH COOH lys Protein Covalent binding due to spontaneous ring opening IgE antibodies were detected in patients with anaphylactic reaction Re-exposure can be life-threatening V. Aminopyrine-Induced Agranulocytosis N N N N N Myeloperoxidase/H2O2/Cl- CH3 O CH3 CH3 CH3 CH3 O CH3 CH3 N CH3 Dication intermediate Associated with a high risk of agranulocytosis (~1%) Reactive dication formed by neutrophil-derived hypochlorous acid could be responsible for the IDR Onset of symptoms (fever, sore throat and infections) in 1 week - 1 month Drug-specific Abs Re-challenge results in rapid drop in neutrophil count as well as their bone marrow precursors V. Halothane-Induced Hepatitis Protein F F Br C F C Cl H Halothane P4502E1 F F O C C Cl F Trifluoroacetyl Chloride F F O C C NH F RM covalently bound to protein Halothane is oxidized by P450 to form trifluroacetyl chloride, which can bind to proteins 20% of patients develop asymptomatic elevation of liver transaminases (AST, ALT) leads to the development of hepatitis hepatitis rarely occurs on first exposure, which suggests that sensitization is required Serum of affected patients contain antibodies against native hepatic proteins as well as trifluoroacetylated proteins (hapten-carrier complex) V. Drugs Known to Cause IDRs Felbamate antiepileptic Nevirapine HIV drug (NNRTI) D-Penicillamine anti-rheumatic Clozapine antipsychotic Carbamazepine anticonvulsant V. Felbamate O Idiosyncratic reactions: CNH 2 O Aplastic Anemia and Liver Toxicity Reactive Metabolite: Yes Protein Binding: Probable Animal Model: No O CNH 2 O Phenylacrolein (Michael Acceptor) H O V. Nevirapine Idiosyncratic reaction: N N N Severe Skin Rash, Liver Toxicity N Reactive Metabolite: quinone methide O H CH3 Protein Binding: Yes; epidermis Animal Model: Yes; Skin rash in the female Brown Norway rat N N N N Quinone Methide O CH2 .. NH2-Protein V. Nevirapine skin rash Human skin in response to NVP treatment Female rat skin in response to NVP treatment V. D-Penicillamine Idiosyncratic reaction: Autoimmunity, lupus Reactive Metabolite: None, parent drug can bind to proteins through the thiol group H2N COOH C CH3 HS CH3 Protein Binding: Yes Animal Model: Yes; Autoimmunity in the male Brown Norway rat Forming mixed disulfides V. Clozapine Idiosyncratic reaction: Agranulocytosis, Liver Toxicity, Cardiac Toxicity CH3 N N N Cl N H Reactive Metabolite: Yes CH3 N Protein Binding: Yes Animal Model: No N N Cl Nitrenium Ion N + V. Carbamazepine Idiosyncratic reaction: Anticonvulsant hypersensitivity syndrome (fever, rash, multiorgan involvement etc.) N O NH2 Reactive Metabolite: Yes Protein Binding: Yes Animal Model: No O N Iminoquinone VI. Methods Ideally want to illustrate each step for each drug: 1. Metabolism 2. Reactive Metabolite Formation 3. Protein Binding in Target Tissue(s) 4. Immunogenicity of Hapten 5. Immune Response IDR VI. Step 1: Metabolism – Microsomes Excise liver Centrifuge 100,000 x g cytosol microsomes Mince liver in sucrose buffer Homogenize Centrifuge 10,000 x g S9 fraction nuclei, cell membrane mitochondria VI. Step 1: Metabolism – Microsomes a) Buffer (physiological conditions, salt/ pH7.4) b) Microsomes c) Drug d) NADPH generating system (NADP+, G6PD, G6P) Incubate at 37C Analyze reaction mixture by HPLC or LC/MS Confirm identity of products with NMR (require pure metabolite) VI. Step 1: Metabolism - Neutrophils Obtain (human / rat) blood Sediment RBCs with dextran Upper solution is placed on top of a ficoll solution (density gradient) Plasma, WBCs RBCs Pour off upper layers, use remaining neutrophils lymphocytes neutrophils Ficoll Centrifuge ~1000 rpm VI. Step 1: Metabolism - Neutrophils a) Buffer (physiological conditions, salt/ pH7.4) b) Neutrophils c) Drug d) Neutrophil activator (PMA) Incubate at 37C Analyze reaction mixture by HPLC or LC/MS Confirm identity of products with NMR (require pure metabolite) VI. Step 2: RM Formation Complete same experiments as when looking at metabolism but with an additional step Reactive metabolite may be so reactive that it is not detected on the HPLC chromatogram Must add GSH or NAC to the reaction mixture to trap the reactive metabolite in a stable form that can be detected by HPLC and later identified by LC/MS and NMR SG N N N N N N N 2B6 N O H N N + N N O OH N CH3 O H N N CH3 O H CH3 OH GSH N O CH3 H VI. Step 3: Protein Binding in Target Tissues Require an antibody that recognizes the reactive metabolite (the hapten) Must prepare antigen by linking the reactive metabolite to an immunogenic carrier protein e.g., KLH Immunize rabbits with this antigen Sera obtained from the blood of these rabbits is polyclonal, and contains antibodies against the hapten VI. Step 3 Cont’d Complete in vivo and in vitro studies in vitro studies are similar to metabolism studies in vivo studies involve administering the drug to animals (rats or mice) In Vivo: Administer drug to rats or mice Isolate and homogenize target tissues VI. Step 3 Cont’d Take tissues from either in vitro or in vivo experiment and perform Western blot analysis to detect covalent binding of reactive metabolites to proteins: • • • • Run the protein sample on an SDS polyacrylamide gel Transfer separated proteins from gel to nitrocellulose membrane Blot membrane with an antibody against the HAPTEN Visualize antibody binding with a detection system; presence of covalent adducts will thus be elucidated VI. Animal Models in Study of IDRs Basically impossible to run prospective clinical trials • Unpredictable nature of IDRs • Ethics Reactions likely involve differences in metabolism/detoxification of reactive metabolites, various aspects of the immune system and perhaps other systems Can not effectively study such complex systems in vitro Lack of animals because IDRs are just as idiosyncratic in animals as it is in humans VI. Nevirapine Animal Model Nevirapine Idiosyncratic skin rash in ~17% of HIV patients in clinical trials Skin lesions in some strains of rats: keratinocyte death, sloughing of skin Nevirapine-Induced Skin Rash in the Female Brown Norway Rat Animal Model? YES! VI. Hopes for the Future To elucidate the mechanism(s) predictability morbidity and mortality Summary IDRs are serious and potentially life-threatening ADRs Quite often formation of drug RMs triggers IDRs RMs are most often formed in liver, bone marrow (peripheral neutrophils), skin and lungs Once formed, RMs bind to nearby tissue entities, inducing immune response and triggering IDRs Discuss: Compare and contrast the use of animal models versus in vitro tests in the study of IDRs.